[Source: The Biodesign Institute] — The Biodesign Institute at Arizona State University, Mapp Biopharmaceutical and Kentucky Bioprocessing (KBP) will collaborate on developing, refining and producing low-cost pharmaceutical products for large cost sensitive markets in global health. The initial product targets include monoclonal antibodies for use in microbicides and mucosal vaccines to prevent transmission of certain infections. The three organizations also expect to collaborate on other products.
Charles Arntzen, PhD, of ASU